| Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-16 14:56:36 |
Czytaj oryginał (ang.) |
| Here's Why Quest Diagnostics (DGX) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-15 14:46:31 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Declares Quarterly Cash Dividend |
SECAUCUS, N.J. , May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. |
prnewswire.com |
2025-05-14 22:17:00 |
Czytaj oryginał (ang.) |
| Should You Continue to Retain DGX Stock in Your Portfolio? |
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions. |
zacks.com |
2025-05-13 12:50:49 |
Czytaj oryginał (ang.) |
| Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds |
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet" Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence early enough (50%) are among the primary reasons cancer recurrence is typically missed, according to oncologists whose patients' cancer recurrence was missed in an earlier stage 94% of oncologists say circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing could reduce diagnosis delays in cancer recurrence but cite hurdles to wide adoption SECAUCUS, N.J. , May 13, 2025 /PRNewswire/ -- Oncologists feel they are seeing more and more patients with advanced cancers, say screening barriers are the leading reason why, and worry that current tests may not catch cancer recurrence early enough, according to a new report, "The Cancer Paradox: Oncologists' Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring. |
prnewswire.com |
2025-05-13 10:03:00 |
Czytaj oryginał (ang.) |
| Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus |
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months. |
zacks.com |
2025-05-05 13:25:34 |
Czytaj oryginał (ang.) |
| Quest Diagnostics: A Leader But Waiting For Better Price |
Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to buy DGX at $140 for a 15% IRR, as the current valuation is high. Valuation analysis shows DGX trading at a premium; base case IRR is 8.46%, below my 15% threshold, warranting a Hold rating. |
seekingalpha.com |
2025-05-03 08:26:04 |
Czytaj oryginał (ang.) |
| These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings |
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday. |
benzinga.com |
2025-04-23 17:17:26 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence |
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion. |
benzinga.com |
2025-04-22 16:09:28 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript |
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Pito Chickering - Deutsche Bank Noah Kava - Jefferies David Westenberg - Piper Sandler Michael Ryskin - Bank of America Andrew Brackmann - William Blair Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics First Quarter 2025 Conference Call. At the request of the company, this call is being recorded. |
seekingalpha.com |
2025-04-22 15:39:04 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up |
DGX delivers solid top-line growth in the first quarter of 2025. |
zacks.com |
2025-04-22 15:35:35 |
Czytaj oryginał (ang.) |
| Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates |
Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago. |
zacks.com |
2025-04-22 12:55:33 |
Czytaj oryginał (ang.) |
| Quest beats quarterly profit estimates on strong demand for diagnostic tests |
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests. |
reuters.com |
2025-04-22 11:37:12 |
Czytaj oryginał (ang.) |
| Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter |
Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow. |
marketwatch.com |
2025-04-22 11:01:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 |
First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80 SECAUCUS, N.J. , April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. |
prnewswire.com |
2025-04-22 10:43:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy? |
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-15 15:06:05 |
Czytaj oryginał (ang.) |
| Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings |
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions. |
zacks.com |
2025-04-15 14:31:16 |
Czytaj oryginał (ang.) |
| DGX Stock Gains Following the Launch of New AD-Detect Blood Test |
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing. |
zacks.com |
2025-04-11 11:45:29 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease |
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J. , April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia. |
prnewswire.com |
2025-04-09 11:53:00 |
Czytaj oryginał (ang.) |
| T-Mobile Leads Five Stocks To Watch As Market Correction Intensifies |
This weekend's stocks to watch are defensive plays. They boast strong relative strength, but still suffered losses amid the market sell-off. |
investors.com |
2025-04-05 12:00:06 |
Czytaj oryginał (ang.) |
| Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? |
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy. |
zacks.com |
2025-02-25 11:55:36 |
Czytaj oryginał (ang.) |
| Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics |
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States. |
prnewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics to Host Investor Day on March 19, 2025 |
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange. |
prnewswire.com |
2025-02-13 18:54:00 |
Czytaj oryginał (ang.) |
| GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System |
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J. |
prnewswire.com |
2025-02-12 11:00:00 |
Czytaj oryginał (ang.) |
| Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-10 12:56:28 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats |
Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024. |
zacks.com |
2025-02-10 12:15:22 |
Czytaj oryginał (ang.) |
| Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-04 12:41:04 |
Czytaj oryginał (ang.) |
| Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-03 12:50:25 |
Czytaj oryginał (ang.) |
| Quest Diagnostics (DGX) is a Great Momentum Stock: Should You Buy? |
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-01-31 15:01:23 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year |
SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies. |
prnewswire.com |
2025-01-30 18:14:00 |
Czytaj oryginał (ang.) |
| Why Quest Diagnostics Stock Was Blasting Higher Today |
Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day. |
fool.com |
2025-01-30 18:07:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Incorporated (DGX) Q4 2024 Earnings Call Transcript |
Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conference Call Participants Kevin Caliendo - UBS Patrick Donnelley - Citi Michael Cherny - Leerink Partners Joanna Zhou - Evercore ISI Pito Chickering - Deutsche Bank David Westenberg - Piper Sandler Andrew Brackmann - William Blair Noah Kava - Jefferies Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics Fourth Quarter and Full-Year 2024 Conference Call. At the request of the company, this call is being recorded. |
seekingalpha.com |
2025-01-30 16:35:58 |
Czytaj oryginał (ang.) |
| Quest Diagnostics EPS Tops Predictions |
Quest Diagnostics (DGX 6.36%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18. |
fool.com |
2025-01-30 13:38:39 |
Czytaj oryginał (ang.) |
| DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise |
Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business. |
zacks.com |
2025-01-30 12:35:51 |
Czytaj oryginał (ang.) |
| Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates |
Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago. |
zacks.com |
2025-01-30 10:55:26 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share |
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80 SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024. |
prnewswire.com |
2025-01-30 08:45:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals |
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND , Jan. 27, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers. |
prnewswire.com |
2025-01-27 10:56:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Quest Diagnostics (DGX) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-24 12:41:08 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock? |
Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024. |
zacks.com |
2025-01-23 10:50:19 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare |
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article. |
zacks.com |
2025-01-17 05:46:10 |
Czytaj oryginał (ang.) |
| Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again |
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-03 15:16:28 |
Czytaj oryginał (ang.) |
| Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025 |
SECAUCUS, N.J. , Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens. |
prnewswire.com |
2025-01-02 13:00:00 |
Czytaj oryginał (ang.) |
| Should You Hold Quest Diagnostics Stock in Your Portfolio Now? |
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well. |
zacks.com |
2024-12-31 10:16:18 |
Czytaj oryginał (ang.) |
| New Health Coaching Service on questhealth.com Set to Boost DGX Stock |
Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health. |
zacks.com |
2024-12-04 10:51:09 |
Czytaj oryginał (ang.) |
| Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference |
SECAUCUS, N.J. , Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m. |
prnewswire.com |
2024-12-03 11:50:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health |
New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health® , a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient engagement services, questhealth.com's Health Coaching pairs individuals with board-certified health advisers who provide personalized support, resources, and education focused on the individual's unique health goals. |
prnewswire.com |
2024-12-03 10:23:00 |
Czytaj oryginał (ang.) |
| Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue? |
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-21 14:36:01 |
Czytaj oryginał (ang.) |
| Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management |
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3η (eta) biomarker in the United States. Quest intends to begin offering the test service to physicians from its advanced laboratory in San Juan. |
businesswire.com |
2024-11-15 15:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy |
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-13 15:00:22 |
Czytaj oryginał (ang.) |
| Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now? |
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive. |
zacks.com |
2024-11-13 11:20:24 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Declares Quarterly Cash Dividend |
SECAUCUS, N.J. , Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025. |
prnewswire.com |
2024-11-12 19:57:00 |
Czytaj oryginał (ang.) |
| DGX vs. PNTG: Which Stock Is the Better Value Option? |
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-11 14:45:40 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain DGX Stock in Your Portfolio Now |
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging. |
zacks.com |
2024-11-04 10:56:09 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? |
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-10-25 14:16:11 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base |
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS dilution. The company faces risks from PAMA reimbursement cuts and labor market challenges but expects long-term growth from organic and acquisition activities. |
seekingalpha.com |
2024-10-24 14:10:29 |
Czytaj oryginał (ang.) |
| Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat |
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227. |
seekingalpha.com |
2024-10-24 12:36:38 |
Czytaj oryginał (ang.) |
| DGX or PNTG: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-10-23 16:45:29 |
Czytaj oryginał (ang.) |
| 4 Stocks to Buy in an Evolving Outpatient Home Health Industry |
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain. |
zacks.com |
2024-10-23 16:05:53 |
Czytaj oryginał (ang.) |
| US lab operator Quest Diagnostics to launch bird flu test at end of October |
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus. |
reuters.com |
2024-10-23 12:08:15 |
Czytaj oryginał (ang.) |
| Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development |
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J. , Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for two emerging infectious diseases recently identified in people in the Americas. |
prnewswire.com |
2024-10-23 11:53:00 |
Czytaj oryginał (ang.) |